Joerg Ludwig

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Brian I. Rini, Arnulf Stenzl, Romauld Zdrojowy et al. · The Lancet Oncology · 2016 · 211 citations

Sunitinib Versus Sunitinib, Urology, Genitourinary Cancer +8

Primary biliary cirrhosis.

Dickson Er, Fleming Cr, Joerg Ludwig · PubMed · 1979 · 53 citations

Hepatic Disorders, Hepatology, Biliary Tract +10

17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC

Brian I. Rini, A. Stenzl, Romuald Zdrojowy et al. · European Journal of Cancer · 2015 · 20 citations

Vaccination, First-line Therapy, Tumor Immunology +10

HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.

Luigi Buonaguro, Andrea Mayer-Mokler, Roberto S. Accolla et al. · Journal of Clinical Oncology · 2018 · 10 citations